Key Points - Rosen Law Firm reminds investors of the September 28, 2026 lead plaintiff deadline for Capricor Therapeutics, Inc. (CAPR) securities purchased between December 17, 2025 and July 26, 2026. - Hagens Berman notes concerns over Capricor's recent Q2 2026 earnings release and lack of management Q&A with analysts, leading to uncertainty and a...
CNFinance Holdings Limited (CNF) - This analysis reviews how the stock price reacted after the last...
LifeVantage Corporation (LFVN) - This analysis reviews how the stock price reacted after the last 12...
Baozun Inc. (BZUN) - This analysis reviews how the stock price reacted after the last 12...
CNFinance Holdings Limited (CNF) - This analysis reviews how the stock price reacted during the last...
Michael Baker from D.A. Davidson issued a price target of $81.00 for CTRN on 2026-08-26 13:39:00.The adjusted price target was set to $81.00.At the time of the announcement, CTRN was...
Ben Hendrix from RBC Capital issued a price target of $2.00 for EHTH on 2026-08-25 11:47:34.The adjusted price target was set to $2.00.At the time of the announcement, EHTH was...
from Craig-Hallum issued a price target of $16.25 for PSNL on 2026-08-24 12:55:17.The adjusted price target was set to $16.25.At the time of the announcement, PSNL was trading at $17.22.The...
from Barrington issued a price target of $14.00 for VMD on 2026-08-24 11:33:30.The adjusted price target was set to $14.00.At the time of the announcement, VMD was trading at $8.85.VMD...
Martin Auster from Raymond James issued a price target of $18.00 for STTK on 2026-08-24 10:06:00.The adjusted price target was set to $18.00.At the time of the announcement, STTK was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
